Page 200 - CW E-Magazine (10-10-2023)

Special Report Special Report

Prometheus is focused on the deve- developing cemdomespib for treating and zigakibart) to treat immuno- platform, Delscape, for developing oral a Laval, Quebec, Canada-based, bio/ may lead to better outcomes for people
lopment of precision medicines for diabetic neuropathic pain. The deal was globulin A nephropathy (IgAN), a rare therapeutic candidates to treat chronic pharmaceutical company. Bellus’ lead living with obesity and obesity-related
treating immune-mediated diseases and approved by the Boards of Directors kidney disease that mostly affects diseases in immunology. DICE’s lead drug candidate is camlipixant, in Phase complications, according to infor-
companion diagnostics. Its lead drug of both companies and is expected to young adults. candidate is DC-806, a small-molecule III development, for the fi rst-line treat- mation from Lilly.
candidate is PRA023 (now known as close in the fourth quarter of 2023. inhibitor of the pro-infl ammatory signal- ment of adult patients with refractory
MK-7240), which is being evaluated Atrasentan is an oral drug in Phase ling molecule, IL-17, a drug target for chronic cough, defi ned as a cough that Sobi’s $1.7-bn acquisition of CTI
for various autoimmune conditions that Astellas’ $5.9-bn acquisition of Iveric III development for IgAN with a pivotal psoriasis and a variety of autoimmune persists for more than eight weeks Biopharma
include ulcerative colitis (UC), Crohn’s Bio readout expected in the fourth quarter and infl ammatory diseases. DICE is also despite optimal treatment of any under- In June 2023, Swedish Orphan Bio-
disease (CD), and systemic sclerosis- In July 2023, Astellas completed of 2023. Atrasentan is also in early- developing oral therapeutic candidates lying conditions or where there is no vitrum (Sobi), a Stockholm, Sweden-
associated interstitial lung disease. In its $5.9-bn acquisition of Iveric Bio, stage development for other rare kidney targeting the integrin α4ß7 for the treat- identifi able underlying cause. based bio/pharmaceutical company
December 2022, Prometheus reported a Parsippany, New Jersey-based bio/ diseases. Zigakibart is a subcutaneously ment of infl ammatory bowel disease. developing drugs for rare diseases, com-
results for MK-7240 from a Phase II pharmaceutical company focused on administered monoclonal antibody, and Lilly’s pending $1.9-bn acquisition pleted its $1.7-bn acquisition of CTI
study for moderate-to-severely active ophthalmology. The acquisition was a Phase III trial in IgAN is expected to The transaction is expected to close of Versanis Bio BioPharma, a Seattle, Washington-based
UC and a Phase IIa study for moderate- announced in late April 2023. start in the fourth quarter of 2023. The in the third quarter of 2023, subject to In July 2023, Eli Lilly and Com- bio/pharmaceutical company develop-
to-severe CD. The drug is a huma- transaction is expected to close in the customary closing conditions, includ- pany agreed to acquire Versanis Bio, ing drugs for blood-related cancers.
nized monoclonal antibody directed Iveric Bio’s lead drug candidate is second half of 2023, subject to custo- ing receipt of required antitrust clea- a New York-based bio/pharmaceutical
to tumour necrosis factor (TNF)-like an avacincaptad pegol for treating geo- mary closing conditions, including rance and the tender of a majority of company focused on cardiometabolic CTI’s lone commercial product
ligand 1A (TL1A), a target associated graphic atrophy, a chronic progressive approval by Chinook’s stockholders the outstanding shares of DICE’s com- diseases, in a deal worth up to $1.9-bn. is Vonjo (pacritinib), which is FDA-
with both intestinal infl ammation and degeneration of the macula as part of and receipt of regulatory approvals. mon stock. Following the successful Versanis’ lead asset is bimagrumab, approved for treating intermediate or
fi brosis. late-stage age-related macular degene- closing of the tender offer, Lilly will a monoclonal antibody that binds high-risk primary or secondary myelo-
ration. The company announced in Sanofi ’s $2.9-bn acquisition of acquire any shares of DICE that are not activin Type II A and B receptors to fi brosis, a rare form of a bone marrow
Prometheus also has a precision February 2023 that the US Food and Provention Bio tendered in the tender offer through a block activin and myostatin signalling. disorder in adult patients who have
medicine platform, Prometheus 360, Drug Administration (FDA) accepted In April 2023, Sanofi completed its second-step merger at the same consi- Bimagrumab is currently being as- platelet (blood-clotting cells) levels
which combines machine learning- the company’s new drug application $2.9-bn acquisition of Provention Bio, deration as paid in the tender offer. sessed in a Phase IIb study alone and in below 50,000/µL. The drug was granted
based analytical approaches with a (NDA) for the drug. The NDA was a Red Bank, New Jersey-based bio/ combination with semaglutide in adults accelerated approval by the FDA in
gastrointestinal bioinformatics data- granted priority review with a Prescrip- pharmaceutical company. Provention GlaxoSmithKline’s $2.0-bn acquisi- who are overweight or obese. Com- 2022. CTI has approximately 144
base to identify therapeutic targets tion Drug User Fee Act goal date of Bio is focused on immune-mediated tion of Bellus Health bining incretins with bimagrumab has employees and had 2022 revenues of
and develop therapeutic candidates to August 19, 2023. diseases. Its lead product, which was In June 2023, GSK completed its the potential to further reduce fat mass approximately $54-mn. CTI is now a
engage those targets. approved by the US FDA in 2022, is $2-bn acquisition of Bellus Health, while preserving muscle mass and wholly-owned subsidiary of Sobi.
The acquisition fi ts one of Astellas’ Tzield (teplizumab-mzwv) for delay-
Biogen’s pending $7.3-bn acquisition fi ve areas of therapeutic focus in the ing the onset of Stage 3 Type 1 diabetes
of Reata Pharmaceuticals company’s growth strategy: developing (T1D) in adults and paediatric patients Chemical Weekly | Import-Export Data
In July 2023, Biogen agreed to treatments for vision loss, blindness, aged eight years and older with Stage 2
acquire Reata Pharmaceuticals, a Plano, and regeneration. The other areas are T1D. Tzield is also in late-stage clini- Market Surveys | Directories
Texas, bio/pharmaceutical company, genetic medicines, immuno-oncology, cal development for the treatment of
for $7.3-bn. Reata specializes in deve- treatments addressing mitochondrial paediatric and adolescent patients that
loping small-molecule therapeutics dysfunction, and targeted protein degra- are newly diagnosed with clinical T1D Business Forums | Expositions
that regulate cellular metabolism and dation to address undruggable drugs in (Stage 3). A Phase III trial is currently
infl ammation in neurologic diseases. various disease areas. underway, and top-line results are The only organisation in India catering exclusively to the needs of the entire chemical industry
Its lead commercial asset is Skyclarys expected in the second half of 2023.
(omaveloxolone) for treating Fried- Novartis’ pending $3.5-bn acquisi- Additional opportunities for the drug Contact:
reich’s ataxia, a rare inherited disease tion of Chinook Therapeutics include re-dosing and formulation, as
that causes progressive damage to the In June 2003, Novartis agreed well as new therapeutic indications.
nervous system and movement pro- to acquire Chinook Therapeutics, a SEVAK PUBLICATIONS PVT. LTD.
blems. The drug was approved by Seattle, Washington-based clinical-stage Lilly’s pending $2.4-bn acquisition
the US Food and Drug Administra- bio/pharmaceutical company, in a deal of DICE Therapeutics 602-B, Godrej Coliseum, K.J. Somaiya Hospital Road,
tion earlier this year (February 2023). worth up to $3.5-bn ($3.2-bn upfront In June 2023, Eli Lilly and Company
The company’s marketing authoriza- and $300-mn in milestone payments). agreed to acquire DICE Therapeutics, a Behind Everard Nagar, Sion (E), Mumbai 400 022.
tion application for omaveloxolone is South San Francisco, California-based Phone: +91-22-24044471 / 72
under review in Europe by the Euro- Chinook’s pipeline includes two bio/pharmaceutical company, for $2.4-bn. Email: admin@chemicalweekly.com
pean Medicines Agency. Reata is also late-stage drug candidates (atrasentan DICE has a proprietary technology

200 Chemical Weekly October 10, 2023 Chemical Weekly October 10, 2023 201

Contents Index to Advertisers Index to Products Advertised